GlassScriptPhysician profile
Annisa L Jamil
NPI 1629006135
$3,277.32
in general payments reported to CMS, 2019-2025
22 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $426 · 2021: $502 · 2022: $354 · 2023: $591 · 2024: $251 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.19 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $611.92 | 2019-2022 | |
| Alcon Vision LLC | $505.75 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Eysuvis, Rocklatan |
| Bausch & Lomb Americas INC. | $335.69 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $335.08 | 2019-2025 | Cequa |
| Abbvie INC. | $279.20 | 2022-2025 | |
| Glaukos Corporation | $196.16 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr, Istent |
| Rxsight INC | $189.19 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $132.16 | 2019-2021 | |
| Sight Sciences, INC. | $106.89 | 2019-2024 | Omni Surgical System |
| Thea Pharma INC. | $93.71 | 2022-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $76.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $76.02 | 2019 | |
| Dompe US, INC. | $65.42 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $51.79 | 2025 | Xdemvy |
| Akorn, INC. | $38.93 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $37.63 | 2021 | |
| Kala Pharmaceuticals, INC. | $34.09 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $27.39 | 2025 | Syfovre |
| Biotissue Holdings INC. | $23.95 | 2025 | |
| Katena Products, INC. (Dba Corza Medical) | $23.08 | 2019 | |
| Tearlab Corp | $19.83 | 2023 | Tearlab Osmolarity System |
| New World Medical,INC. | $17.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annisa Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.